vs
ADMA BIOLOGICS, INC.（ADMA）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是ADMA BIOLOGICS, INC.的1.2倍（$173.1M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 4.9%，领先30.6%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 3.6%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $11.8M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 10.8%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
ADMA vs PLPC — 直观对比
营收规模更大
PLPC
是对方的1.2倍
$139.2M
营收增速更快
ADMA
高出14.8%
3.6%
净利率更高
ADMA
高出30.6%
4.9%
自由现金流更多
ADMA
多$22.8M
$11.8M
两年增速更快
ADMA
近两年复合增速
10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $173.1M |
| 净利润 | $49.4M | $8.4M |
| 毛利率 | 63.8% | 29.8% |
| 营业利润率 | 45.1% | 6.8% |
| 净利率 | 35.5% | 4.9% |
| 营收同比 | 18.4% | 3.6% |
| 净利润同比 | -55.9% | -19.3% |
| 每股收益（稀释后） | $0.20 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAPLPC
| Q4 25 | $139.2M | $173.1M | ||
| Q3 25 | $134.2M | $178.1M | ||
| Q2 25 | $122.0M | $169.6M | ||
| Q1 25 | $114.8M | $148.5M | ||
| Q4 24 | $117.5M | $167.1M | ||
| Q3 24 | $119.8M | $147.0M | ||
| Q2 24 | $107.2M | $138.7M | ||
| Q1 24 | $81.9M | $140.9M |
净利润ADMAPLPC
| Q4 25 | $49.4M | $8.4M | ||
| Q3 25 | $36.4M | $2.6M | ||
| Q2 25 | $34.2M | $12.7M | ||
| Q1 25 | $26.9M | $11.5M | ||
| Q4 24 | $111.9M | $10.5M | ||
| Q3 24 | $35.9M | $7.7M | ||
| Q2 24 | $32.1M | $9.4M | ||
| Q1 24 | $17.8M | $9.6M |
毛利率ADMAPLPC
| Q4 25 | 63.8% | 29.8% | ||
| Q3 25 | 56.3% | 29.7% | ||
| Q2 25 | 55.1% | 32.7% | ||
| Q1 25 | 53.2% | 32.8% | ||
| Q4 24 | 53.9% | 33.3% | ||
| Q3 24 | 49.8% | 31.1% | ||
| Q2 24 | 53.6% | 31.9% | ||
| Q1 24 | 47.8% | 31.3% |
营业利润率ADMAPLPC
| Q4 25 | 45.1% | 6.8% | ||
| Q3 25 | 38.0% | 7.4% | ||
| Q2 25 | 35.1% | 10.1% | ||
| Q1 25 | 30.4% | 8.8% | ||
| Q4 24 | 32.6% | 10.5% | ||
| Q3 24 | 33.1% | 7.1% | ||
| Q2 24 | 36.6% | 8.1% | ||
| Q1 24 | 26.7% | 8.2% |
净利率ADMAPLPC
| Q4 25 | 35.5% | 4.9% | ||
| Q3 25 | 27.1% | 1.5% | ||
| Q2 25 | 28.1% | 7.5% | ||
| Q1 25 | 23.4% | 7.8% | ||
| Q4 24 | 95.2% | 6.3% | ||
| Q3 24 | 30.0% | 5.2% | ||
| Q2 24 | 29.9% | 6.8% | ||
| Q1 24 | 21.7% | 6.8% |
每股收益（稀释后）ADMAPLPC
| Q4 25 | $0.20 | $1.72 | ||
| Q3 25 | $0.15 | $0.53 | ||
| Q2 25 | $0.14 | $2.56 | ||
| Q1 25 | $0.11 | $2.33 | ||
| Q4 24 | $0.45 | $2.13 | ||
| Q3 24 | $0.15 | $1.54 | ||
| Q2 24 | $0.13 | $1.89 | ||
| Q1 24 | $0.08 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | — |
| 总债务越低越好 | $72.1M | $38.3M |
| 股东权益账面价值 | $477.3M | $475.5M |
| 总资产 | $624.2M | $653.6M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资ADMAPLPC
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
总债务ADMAPLPC
| Q4 25 | $72.1M | $38.3M | ||
| Q3 25 | $72.4M | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | $72.3M | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | — | $55.0M |
股东权益ADMAPLPC
| Q4 25 | $477.3M | $475.5M | ||
| Q3 25 | $431.2M | $466.3M | ||
| Q2 25 | $398.3M | $460.7M | ||
| Q1 25 | $373.4M | $435.8M | ||
| Q4 24 | $349.0M | $422.3M | ||
| Q3 24 | $231.9M | $429.0M | ||
| Q2 24 | $188.3M | $416.2M | ||
| Q1 24 | $153.7M | $413.4M |
总资产ADMAPLPC
| Q4 25 | $624.2M | $653.6M | ||
| Q3 25 | $568.7M | $644.6M | ||
| Q2 25 | $558.4M | $631.5M | ||
| Q1 25 | $510.6M | $592.5M | ||
| Q4 24 | $488.7M | $573.9M | ||
| Q3 24 | $390.6M | $592.0M | ||
| Q2 24 | $376.4M | $572.6M | ||
| Q1 24 | $350.9M | $586.1M |
负债/权益比ADMAPLPC
| Q4 25 | 0.15× | 0.08× | ||
| Q3 25 | 0.17× | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | 0.21× | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $11.8M |
| 自由现金流率自由现金流/营收 | 24.8% | 6.8% |
| 资本支出强度资本支出/营收 | 0.8% | 5.9% |
| 现金转化率经营现金流/净利润 | 0.72× | 2.60× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $33.3M |
8季度趋势，按日历期对齐
经营现金流ADMAPLPC
| Q4 25 | $35.6M | $21.9M | ||
| Q3 25 | $13.3M | $18.9M | ||
| Q2 25 | $21.1M | $26.9M | ||
| Q1 25 | $-19.7M | $5.7M | ||
| Q4 24 | $50.2M | $24.1M | ||
| Q3 24 | $25.0M | $9.4M | ||
| Q2 24 | $45.6M | $28.3M | ||
| Q1 24 | $-2.2M | $5.8M |
自由现金流ADMAPLPC
| Q4 25 | $34.6M | $11.8M | ||
| Q3 25 | $-1.1M | $8.3M | ||
| Q2 25 | $18.7M | $18.6M | ||
| Q1 25 | $-24.4M | $-5.3M | ||
| Q4 24 | $47.5M | $20.6M | ||
| Q3 24 | $24.0M | $5.8M | ||
| Q2 24 | $43.6M | $24.6M | ||
| Q1 24 | $-4.6M | $1.8M |
自由现金流率ADMAPLPC
| Q4 25 | 24.8% | 6.8% | ||
| Q3 25 | -0.8% | 4.7% | ||
| Q2 25 | 15.3% | 10.9% | ||
| Q1 25 | -21.2% | -3.6% | ||
| Q4 24 | 40.4% | 12.3% | ||
| Q3 24 | 20.0% | 3.9% | ||
| Q2 24 | 40.7% | 17.7% | ||
| Q1 24 | -5.6% | 1.3% |
资本支出强度ADMAPLPC
| Q4 25 | 0.8% | 5.9% | ||
| Q3 25 | 10.7% | 6.0% | ||
| Q2 25 | 2.0% | 4.9% | ||
| Q1 25 | 4.1% | 7.4% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 0.9% | 2.4% | ||
| Q2 24 | 1.9% | 2.7% | ||
| Q1 24 | 2.9% | 2.8% |
现金转化率ADMAPLPC
| Q4 25 | 0.72× | 2.60× | ||
| Q3 25 | 0.36× | 7.21× | ||
| Q2 25 | 0.62× | 2.12× | ||
| Q1 25 | -0.73× | 0.49× | ||
| Q4 24 | 0.45× | 2.30× | ||
| Q3 24 | 0.70× | 1.22× | ||
| Q2 24 | 1.42× | 3.02× | ||
| Q1 24 | -0.12× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PLPC
暂无分部数据
